1
Introduction
On a worldwide scale, colorectal cancer is one of the leading causes of cancer deaths,
affecting millions of people every year. One third of colorectal cancer concerns the
rectum. In more than two thirds of the cases rectal cancer is still localised to the
pelvis without detectable metastases. In these cases surgical resection is the cornerstone
for a curative approach. Since the introduction of the combined abdomino-perineal
resection by Miles and Quénu around the beginning of the 20th century [1], rectal
cancer became a curable disease. However, for many decades the results of surgery
have been disappointing, as it was often spoiled by a local recurrence rate of up
to 40% or even higher. Uncontrolled progressive local recurrences, hardly palliated
by irradiation or chemotherapy, have brought a miserable death to tens of millions
of patients.
This situation lasted till the end of the last century when the anatomical basis of
rectal cancer surgery was revived by Heald and Quirke [2,3]. Quirke demonstrated that
the radial margin between the tumour border and the surgical resection margin was
a strong prognosticator for local recurrence. He pointed out that both tumour progression
and surgical quality were important for a safe margin. Poor surgery with incomplete
mesorectum or tears into the mesorectal fat or muscular tube of the rectum could reduce
this margin and consequently lead to local recurrences. Heald introduced the principle
of total mesorectal excision (TME). In doing so he defined the optimal quality of
surgery.
Worldwide surgeons have accepted as standard of care that optimally the rectum has
to be removed within its enveloping mesorectal fascia. TME emphasises the importance
of an anatomical resection in the planes between the mesorectal fascia and the surrounding
pelvic fascias. However, the principle of resection of the rectum within its mesorectal
fascia seems to fail when analysing low rectal cancer. From the early randomised controlled
trials it was learned that patients requiring an abdomino-perineal excision (APE)
still had high positive circumferential resection margins [4–7]. The lower rectum
and anorectum are not surrounded by a protecting layer of mesorectal fat. Instead,
already in an early stage, progressing tumours reach and possibly infiltrate the pelvic
floor muscles, which are continuous with the external sphincter more distally. Compared
with patients undergoing low anterior resection (LAR) APE patients have tumours located
lower and more advanced, therefore new principles of surgery had to be developed [8].
Results of lower rectal cancer surgery improved when the principle of the extra levator
approach was introduced [9–12]. This involves removal of the lower rectum during an
abdomino-perineal excision en bloc with the external sphincter and levator ani muscles.
In the lower rectum the role of complete removal of the mesorectal fascia is replaced
by removal of the levator ani muscles. Again, the quality of the surgery can be judged
by the completeness of this resection.
Modern rectal cancer surgery can be tailored to the specific topographical relationships
of the tumour. In proximal tumours the mesorectal fascia acts as the guiding structure.
Transection of the specimen can be performed 4–5 cm distally from the lower tumour
border or at the pelvic floor when the mesorectum terminates higher. More distal tumours
can be removed by either intersphincteric resection – if the tumour is confined within
the smooth muscle tube of the muscularis propria, sometimes even allowing for a colo-anal
anastomosis – or extralevator resection if the pelvic floor is threatened or already
involved by tumour progression. The third option for an abdomino-perineal excision
is to take an even wider approach, taking out the ischiorectal fat en bloc with the
levator muscles, if the tumour has perforated or fistulated through the pelvic floor
muscles into this fatty area. However, this will be the case only in extremely rare
circumstances.
Modern rectal cancer surgery is part of a multidisciplinary approach. Preoperative
imaging with magnetic resonance imaging (MRI) is able to delineate the tumour very
accurately and helps to select those patients requiring downsizing and down-staging,
optimising the chances of a good tumour resection [13–15]. The pathologist plays an
important role in the feedback to the surgeon, which is necessary to improve surgical
outcome [16].
The first step in integration of optimal imaging, treatment modalities and pathology
is taken is several countries. The next step will be to optimise treatment for the
individual patient, who is interested not only in the oncological outcome but also
in functional results and subsequent quality of life. Avoiding and decreasing morbidity,
especially in the elderly, will require the development of new innovative strategies.
2
Contribution of pathology to the anatomical approach
It may seem odd to start a discussion on modern surgical approaches to localised rectal
cancer with the findings of the pathologist. However, it was a pathologist who demonstrated
the importance of the distance of the radial tumour border to the mesorectal fascia,
which is called the circumferential resection margin (CRM) in TME surgery [3].
In 2002 Nagtegaal analysed the data of the Dutch TME study, and she confirmed that
in 44% of the patients the involved circumferential resection margin was the result
of poor-quality surgery. It was also shown that, after incomplete mesorectal excision,
the overall recurrence rate was almost doubled, which could be attributed mainly to
the excess of local recurrences [16]. Nagtegaal and Quirke performed a meta-analysis
on the importance of the CRM in more than 17,500 patients and concluded that CRM involvement
predicts not only local recurrence but also distant metastasis and subsequent overall
survival. Failure to achieve a negative CRM after neoadjuvant treatment leads to a
poorer prognosis compared with no neoadjuvant treatment. Possibly the explanation
for this is the selection of patients with tumours more resistant to therapy. This
finding could be an argument for restaging after neoadjuvant therapy, and to consider
more prolonged neoadjuvant treatment, or to refer to a specialised centre for more
extended resection or additional boosting of the area at risk [17].
Thus, the actual feedback of the pathologist to the surgeon should contain information
on the CRM and quality of surgery [18]. Another important issue, which will be discussed
later in this paper, is the evaluation of the effectiveness of the chosen neoadjuvant
treatment. Preferably, macroscopic images of the resected specimens, as well as the
microscopic images, should be available for internal audit and continued education
and improvement of all member decisions during the multidisciplinary tumour board
meetings.
Quirke proposed a 3-point grading system for the evaluation of the macroscopic specimen
for both low anterior and abdomino-perineal resections. Good surgery would be qualified
by an intact mesorectal fascia with only minor irregularities, or in the case of APE,
a specimen with levator ani and external sphincters without any defects deeper than
5 mm and the levator ani attached to the mesorectal fascia [19,20] (see Figs. 1–3).
After moderate-quality surgery the bulk of the mesorectum is removed but shows an
irregular surface, however still without exposing the muscularis propria or perforations.
In the case of an APE, a specimen which shows waist formation, indicative for a less
complete levator ani covering at the anorectal junction, but with intact sphincters,
signifies a moderate quality of surgery.
Poor surgery would be characterised by severe irregularities on the surface of the
specimen, exposing the muscularis propria or internal sphincter or even showing perforations
to the lumen.
Very essential for the grading of the APE specimen is the question of whether the
levator ani muscle is still attached to the mesorectum. Thus, waist formation is avoided
and the result is a more cylindrical resection. In order to achieve optimal feedback,
pathology reports should be standardised, not only regarding the reporting of the
TNM status, but also on the quality of surgery [19].
3
The importance of MRI for the surgical treatment of rectal cancer
Magnetic resonance imaging (MRI) is a reliable diagnostic tool for clinical staging
of rectal cancer, but other imaging methods for the pelvis are also being used for
this purpose. Computed tomography (CT) is able to identify enlarged lymph nodes, although
it is not accurate for assessing the morphology of these nodes. Furthermore, the contrast
resolution of CT is insufficient to reliably assess involvement of the surgical resection
plane in mid and lower rectal cancer. CT, however, is indicated for distant staging
of metastatic disease and, if there is no easy access to an MRI, for assessment of
resectability of high rectal tumours [21–23]. Endorectal ultrasound (EUS) cannot visualise
the mesorectal fascia, but is the modality of choice to differentiate between T1 and
T2 lesions for the selection of local therapies. EUS has a high sensitivity to stage
depth of submucosal involvement [24]. However, MRI is the king of kings of all imaging
modalities in its tissue contrast resolution and provides the necessary detailed anatomical
information on pelvic fascias and dissection planes between pelvic soft tissues, which
sets the scene for the planning of the resection.
Without the anatomical topographical information of an MRI, the surgeon has to rely
on ad hoc decisions when unexpected problems occur during the actual surgical procedure
and in a worst-case scenario these problems may even go unnoticed, or have become
irreversible. With the anatomical information from MRI critical sites of resection
can be anticipated and addressed before surgery: i.e. use of neoadjuvant treatment
or referral to a centre specialised in extended extra anatomical pelvic resection
if TME surgery is not justified.
The Mercury study group reported the reliability of MRI on predicting extramural depth
of tumour invasion. Very good correlation of extramural spread on MRI and histopathology
was found: the 95% confidence interval being <0.5 mm. The TNM classification lacks
specificity in the T3 stage [25]. A T3 tumour with limited extramural spread (outside
the muscularis propria) has a different prognosis to a T3 tumour with more extended
spread. Merkel et al demonstrated that a cut-off point of 5 mm spread divided patients
into groups with good and poor prognoses, provided that a safe CRM was obtained [26].
For the surgeon it is important that patients with limited extramural spread can be
treated as T2 patients, and in most cases will not require neoadjuvant treatment with
its associated adverse effect on surgical morbidity and functional outcome.
Even more important from the surgical technical point of view is the fact that MRI
can reliably anticipate an involved circumferential resection margin. MRI differentiates
between high-risk (<1 mm) and low-risk (>1 mm) patients for local recurrence. MR CRM
margins >1 mm and <2 mm, >2 and <5 and >5 mm carried a similar risk for local recurrence
of around 7%, in contrast to the 20% risk of patients with an anticipated margin of
<1 mm [27]. The ability to predict a 1-mm free margin was recently confirmed by a
German group [28].
The ability of MRI to discriminate between positive and negative lymph nodes is quite
disappointing. Like other imaging modalities, conventional MRI without any MR contrast
lacks both sensitivity and specificity to identify or rule out positive nodes, and
cannot reliably be used for treatment stratification [29,30]. Size has been an unreliable
variable to predict nodal involvement [31,32]. Several contrast agents have been and
are under investigation, but at the time of writing results are still inconclusive
[33–35]. Diffusion-weighted MRI imaging (DWI) shows a high signal in both benign and
malignant nodes and therefore cannot differentiate between the two. A restaging MRI,
including DWI, has a high negative predictive value (NPV) for the detection of nodal
metastases and can be more reliably used for nodal restaging after neoadjuvant treatment
[36]. The most reliable variable seems to be the evaluation of nodal morphology, such
as roundness, irregular border or heterogeneous texture. However, this is difficult
and subject to large inter-observer variability, especially in nodes <6 mm and in
patients with only small nodes of limited value in clinical practices [31,37]. MRI
plays an important role in the evaluation of response to neoadjuvant treatment (NT)
and the consequences for the final surgical resection. NT is able to downsize the
tumour. In particular, large tumours may have been over-staged at the initial MRI.
Sometimes a pushing tumour border seen on primary staging MRI may be mistaken for
an infiltrating one. Restaging with MRI after NT may reveal surgical dissection planes
which were obscured at the primary staging MRI. As a consequence, surgical planning
can be more conservative.
Clinical T and N stage may also alter after NT and allow a change in surgical approach.
MRI is furthermore accurately correlated with histopathological down-grading of the
tumour. Apart from opening new possibilities for a minimal invasive surgical approach
for the very good responders, non-responders can be identified who may require intensification
of the treatment plan [38–44].
In order to understand the consequences of NT, it is of crucial importance that radiologists
and pathologists participate in the multidisciplinary treatment team.
4
Role of neoadjuvant treatment for the surgeon
The primary objective in rectal cancer surgery is to achieve a free surgical resection
margin. The purpose of NT is twofold: first, to sterilise the potential tumour-cell-bearing
volume in the pelvis, which is not removed during surgery, more specifically the lateral
zones of lymphatic spread; and second, to change the size and stage of the primary
rectal cancer in order to facilitate surgical resection and even to allow for more
limited surgery. In Japan the lateral lymph nodes are removed as standard procedure
during rectal cancer surgery. By doing so, NT can be safely omitted according to the
Japanese workers. Comparison between the Japanese results with extended lymphadenectomy
and the Dutch TME study (which randomised between TME surgery with and without 5 × 5 Gy
preoperative radiotherapy) showed that 5 × 5 with standard TME surgery was as effective
as extended lateral lymphadenectomy for the prevention of local recurrences [45].
The Swedish Rectal Cancer Trials, the Dutch TME study and the British CRO7 study have
clearly demonstrated that preoperative 5 × 5 Gy followed by immediate surgery (preferably
within 1 week) yields excellent oncological results in patients in whom a CRM-negative
margin can be achieved [46–49]. A recent update of the third Swedish Rectal Cancer
Trial shows that a waiting period after 5 × 5 Gy short-course radiotherapy effectively
reduces postoperative morbidity, while also a down-staging effect was noticed [50].
In contrast, advanced tumours, invading the mesorectal fascia or even penetrating
into the surrounding pelvic structures, would inevitably lead to positive surgical
margins if the surgeon sticks to the principle of dissection along the mesorectal
fascia. These patients require a more extended resection, peripheral to the mesorectal
fascia. In the pelvis with organs packed tightly together these extended resections
often result in loss of autonomic nerves, other pelvic supporting structures (sacrum,
pelvic floor muscles) or organs (bladder, genital organs and ureters). Preoperative
treatment with radiotherapy and concomitant chemotherapy can effectively downsize
and even down-stage locally advanced tumours and thus take away the threat of an involved
margin, allowing for a more preservative approach [51–53]. Whereas the lateral margin
is influenced by NT, it is not evident that the distal margin moves upwards, or that
it is possible or even wise to perform a low anastomosis in a previously irradiated
part of the (ano-)rectum [54,55].
Systemic chemotherapy may also be incorporated into an NT scheme. In metastasised
patients it helps to select the responders, who may be good candidates for metastasectomy
as well as resection of the primary from those patients who are progressive and would
not benefit from extended surgery [56]. The Dutch Colorectal Cancer Group initiated
the international RAPIDO study, which seeks to find answers for the question of whether
upfront systemic chemotherapy as part of NT can reduce the occurrence of metastases
in localised rectal cancer [57].
5
The anatomical surgical approach to localised rectal cancer
The surgical approach is based on the preoperative MRI image and may also take into
account the response to neoadjuvant treatment. The resection itself follows anatomical
principles and is based on removal of the rectum within its covering mesorectal fascia.
In proximal tumours, the distal rectum may be preserved, provided that at least 4–5 cm
of the mesorectum is removed distally from the tumour [58]. In low rectal cancers
at the anorectal junction or below, depending on the infiltration depth of the tumour,
the pelvic floor muscles and external sphincter often need to be removed en bloc with
the rectum to assure a complete resection with a CRM of more than 1 mm [10,11].
A secondary objective is to avoid damage to the nerve system as little as possible.
The pelvic autonomic nerves consist of a fine network originating around the aorta,
which descends as a fine mesh lining the mesorectal fascia. The hypogastric nerves
condense and split into two lateral bundles which can easily be identified and followed
to the inferior hypogastric plexus. In this area innervation, lymphatic drainage and
blood supply mingle in the lateral pillars of the rectum. The nervi erigentes also
join the inferior hypogastric plexus from the dorsolateral and also lie in close approximation
to the dorsolateral mesorectal fascia. The somatic levator ani and pudendal nerves
are protected by the pelvic fascia and are less at risk than the autonomic nerves
[59].
The anterior mesorectum distally to the peritoneal reflection is thin, but, similarly
to the rest of the mesorectum, is also covered with a fascia-like structure (fascia
of Denonvilliers), which allows for dissection of the anterior mesorectal fascia from
the prostate/vesicles or posterior vaginal wall [60,61]. More distally, this layer
ends and is replaced by intertwining bundles of somatic perineal muscles joining with
the smooth muscular layer of the muscularis propria of the anorectum. This organisation
of muscle fibres anchors the anorectum to the pelvis. More laterally and dorsally
at the level of the sphincters, the adherence of the smooth muscles to the surrounding
external sphincter muscles is much more loosely organised. The external sphincter
may be considered the distal part of the funnel shaped pelvic floor muscles enveloping
the smooth-muscular layer of the internal sphincter. As mentioned above, laterally
and dorsally the adherence between internal and external sphincters is low and allows
for the development of an intersphincteric resection plane. On the anterior side the
somatic pelvic floor muscles, which distally join in a tendinous perineal body, are
very adherent to the anterior part of the anal rectum. Therefore no such thing as
an intersphincteric dissection plane is present on the anterior side of the distal
rectum [62]. This is a very important anatomical fact which influences the way low
rectal tumours can be dissected. An abdomino-perineal excision (APE) can be performed
in three dissection planes: (1) the intersphincteric plane which is close to the internal
sphincter and suitable only for tumours which are confined to the muscularis propria
of the rectum; (2) the extralevator plane which follows the external fascia of the
external sphincter continuously along the external fascia of the levator ani muscles
and transects these muscles as laterally as possible before entering the abdomen;
and (3) the ischiorectal plane which also removes the ischiorectal fat and which follows
the external fascia of the pelvis, removing the ischiorectal fat en bloc with the
levator ani muscles. Again, the abdomen is entered as laterally as possible at the
level of the attachment of the levator ani muscles to the pelvic wall see (Fig. 4).
In most distal rectal carcinomas the extralevator abdomino-perineal excision (ELAPE)
is recommended to achieve a complete resection with a negative CRM [63]. Either the
patient may be operated in a supine position with the legs in movable stirrups, or
the patient may be turned to prone position for the perineal resection [64]. When
the operation is performed in the supine position the patient does not need to be
turned and the procedure can start with either the perineal phase or the abdominal
phase.
In the supine position the dissection starts with an incision around and subsequent
closure of the anus [10,19] (Fig. 5). The external perineal fascia which covers the
external sphincter can be followed up to the lateral attachment of the levator ani
to the pelvic sidewall. At this level the levator ani can be cut, exposing the mesorectum.
Dorsally, the anococcygeal ligament has to be transected. Depending on the location
of the tumour, the presacral space may be entered ventrally to the coccyx, or in dorsally
located tumours, the coccyx may be removed to enter the presacral space. After transection
of the levator on both sides, exposing the mesorectum and opening the presacral space
exposing the dorsal part of the distal mesorectum, the anterior dissection may commence.
The anterior part of the levator ani muscle encloses the internal genital organs and
needs to be transected at the level of Denonvilliers’ fascia. After exposing Denonvilliers’
fascia the dissection continues distally; retracting the specimen dorsally helps to
identify the somatic perineal muscles, which are closely adherent to the anorectum.
The transection takes place in the somatic muscles, avoiding a fausse route into the
bowel. If the operation was not started with the abdominal phase, the abdomen is opened
now. Dissection is according to TME principles, avoiding nerve damage. As the pelvic
floor muscles are already transected, taking out the specimen is a relatively uncomplicated
procedure.
If the operation is performed in prone position, the procedure most often starts with
the abdominal phase, with the patient lying in supine position [65] (Fig. 6). Again,
care must be taken not to push the dissection too deep down because of the risk of
coning in, resulting in dissection of the pelvic floor off the mesorectum and subsequent
waist formation. However, it is important to develop the presacral space until the
os coccygis is exposed. On the lateral side the low hypogastric plexus has to be dissected
off the mesorectum and the lateral pillars also have to be transected. Denonvilliers’
fascia has to be exposed before the abdominal phase can be ended and the patient can
be turned into prone position for the perineal phase.
In prone position a teardrop like incision is made around the anal skin and extended
proximally above the ano-coccygeal joint. After closure of the anus, the deep perineal
fascia is followed from the external sphincter to the lateral attachments of the levator
ani. After the coccyx has been cut, the already opened presacral space is entered
and the lateral attachments of the levator ani can be cut. After arriving at the level
of Denonvilliers’ fascia, the specimen can be everted through the perineal wound and
the dissection of the anterior plane of the specimen commences under direct vision.
First, the puborectal sling has to be cut, as also the deep perineal muscles which
are closely adherent to the anterior part of the anorectum. Again the dissection is
carried out proximally to distally. Cutting the perineal body is the last part of
the operation before the specimen is taken out. Care must be taken not to damage the
urethra and the neural bundles of Walsh, which are very close to this dissection plane.
In both positions a complete extralevator abdomino-perineal excision can be performed.
In prone position visibility of the perineal operating field is better at the cost
of a wider incision, which requires closure with a (biological) mesh or musculo-cutaneous
flap [9]. In the supine position simultaneous access to the tumour from the abdomen
and perineum may be an advantage in more advanced tumours. An intersphincteric or
ischiorectal approach is more commonly performed in supine position. In both positions,
the abdominal phase may also be performed laparoscopically.
6
Future perspectives
6.1
Registry
On a population-based level, outcome of rectal cancer treatment differs not only widely
among countries, but also within countries among hospitals and even within hospitals
among individual surgeons [18,66–68]. But in the end, the chain of treatments given
to an individual patient can be traced back to each individual link of the chain.
If the quality of pathology is excellent, it will enable one to unravel the different
prognostic variables which apply to an individual patient. Not only can the biology
of the tumour be ascertained but also the quality of surgery and the effect of neoadjuvant
treatment. Furthermore the anatomical information from the MRI may be linked to the
outcome and quality of the surgical procedure.
Registration of these variables will identify the weak links and will allow better
quality of the complete chain, improving outcome and reducing the burden of treatment
costs for avoidable poor results [69] (Fig. 7).
Localised rectal cancer – but also metastasised rectal cancer – must be treated by
a multidisciplinary team. In order to achieve the best quality of treatment, the planning
of the treatment and the sequence of the different treatment modalities have to be
decided upon before any treatment is given. During a multidisciplinary team meeting
(MDT), after the results of imaging and histopathological biopsies have become available,
the specific problems of a rectal cancer can be identified and the best approach for
the individual patient may be selected, depending on the presence/exclusion of metastatic
disease, local extent of the tumour and the patient’s condition. It is important for
the patient to know who has the role of the director of the treatment. In most cases
this responsibility lies with the surgeon, who is responsible not only for the surgery
but for all components involved in the treatment planning.
On a local level the use of standard protocols, the registration of the MDT meetings
and the registration of the important outcome parameters can help to identify blind
spots. These data can constitute the basis for a larger – possibly national – registry
[70]. These national registries can be used to compare countries. In Norway, Sweden,
Denmark, the UK and the Netherlands mandatory registration has led to almost 100%
coverage of the population.
EUROCARE collects colorectal cancer data from all European countries and was able
to show large differences in outcome in Europe [66].
A limitation on the overall use of the EUROCARE database is the wide spread in coverage
of their populations between the European countries. It is difficult to compare results
between countries with coverage of less than 50% and countries with coverage of 100%.
Furthermore, the completeness of important clinical data such as stage distribution
and cancer subsites varies widely between registries. For example, the United Kingdom
had poorer oncological results than France and Germany; however, the UK has coverage
of 100% compared with coverage of 18% and 1% respectively for France and Germany.
Explaining difference in outcome between countries with different coverage is difficult,
particularly when it is unclear whether coverage of less than 50% is representative
for the country as a whole.
But then again, there is no need to create a scale of the outcome of different countries.
It is more relevant to identify the best practice and to set European guidelines based
on the best knowledge available [71,72]. The EURECCA colorectal project, which promotes
registry based on consensus and subsequent sharing of data, can lead to a better outcome
for rectal cancer patients all over the world [66,73–76].
6.2
Centralisation
With the improvement in care during the last decades and the introduction of MDT meetings,
the oncological outcome of rectal cancer has greatly improved. Another more recent
development and improvement in cancer care is the introduction of centralisation of
care for advanced cases and major surgery. In rectal cancer this also plays an important
role. In advanced cases the cancer grows through its surrounding fascia into other
organs and structures. In those advanced cases, when an exenteration is needed, the
resection could consist of an orthopaedic, gynaecological and urological en bloc resection
combined with the rectal resection. It is not desirable that such a procedure is performed
by multiple surgeons. Therefore the rectal cancer surgeon has to be a complete pelvic
surgeon. However, normally these advanced cases have a low incidence in a normal regional
hospital. The small numbers increase the risk of performing an irradical resection
as the experience with these cases is limited. Centralisation of advanced rectal cancer
cases will not only result in less irradical resections but also in better postoperative
care. As a hospital treats more advanced cases, all specialties involved in rectal
cancer care gain more experience. Furthermore postoperative complications are seen
sooner, radiological imaging is interpreted better by the radiologist and pathologists
gain more experience with large specimens and the influence of neoadjuvant treatment.
All this will result in lower mortality rates and better oncological outcome. Specialisation
has led to improved outcome in rectal cancer treatment; how much more this will be
true for locally advanced cases requiring more individualised surgery [77–79].
6.3
Patient reported outcome measures
Due to the major improvements in therapy and oncological outcome in the last decades,
the influence of treatment on the individual patient has become more and more important.
Particularly in the last decade, where outcome of a disease is not the only measurement
of adequate treatment, there is an increasing interest in the influence of treatment
on patients’ quality of life (QOL). Most of the studies published on quality of life
and rectal cancer use generally used questionnaires such as the sf-36, EORTC QLQ-C30
OR EORTC QLQ-C38. These questionnaires are reliable, valid and responsive, but have
not been developed to assess treatment on an individual level [80–82].
The modern rectal cancer patient is confronted with a combination of treatments, all
of which will to a certain extent influence his way of living. The patient would probably
like to be informed about alternatives in their treatment schedule and about the consequences
of their choice.
It is important for future research to focus on different and more interesting patient
groups, such as frail and elderly patients. In these patients, it is more likely that
the assumed benefits of survival give an increase in morbidity and could have an adverse
effect on QOL. Future studies on rectal cancer have not only to focus on the effect
of additional treatments on survival, but also the influence of the treatment on QOL.
If the treatment results in increase in QOL, is the possible consequent decrease in
QOL worthwhile? It is likely that these studies will make the decision process easier
for the involved specialties in the treatment of rectal cancer and will result in
a more patient-tailored treatment.
7
Conclusion
Surgery is still the cornerstone of rectal cancer treatment for the time being. Therefore,
the surgeon should take the role of the director of the treatment plan, and should
realise that surgery is an integral part of a comprehensive multidisciplinary approach.
The basis for quality assurance is registration. A modern anatomical surgical approach
requires also a modern attitude towards quality assurance and an obligation to keep
the patient well informed about the choices which have been made and to allow the
patient to have his/her own say in the matter.
Conflict of interest statement
None declared.